Synonym
130714-47-5; Sdz-wag-994; SDZ WAG 994; n-cyclohexyl-2'-o-methyladenosine; Adenosine, N-cyclohexyl-2'-O-methyl-
IUPAC/Chemical Name
(2R,3R,4R,5R)-5-(6-(cyclohexylamino)-9H-purin-9-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol
InChi Key
JAKAFSGZUXCHLF-LSCFUAHRSA-N
InChi Code
InChI=1S/C17H25N5O4/c1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10/h8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21)/t11-,13-,14-,17-/m1/s1
SMILES Code
CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C=NC3=C2N=CN=C3NC4CCCCC4
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
363.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Klaft ZJ, Duerrwald LM, Gerevich Z, Dulla CG. The adenosine A1 receptor
agonist WAG 994 suppresses acute kainic acid-induced status epilepticus in vivo.
Neuropharmacology. 2020 Oct 1;176:108213. doi: 10.1016/j.neuropharm.2020.108213.
Epub 2020 Jun 29. PMID: 32615188; PMCID: PMC7530074.
2: Cramer JA, Pasternak SJ, Athill LV. A tandem solid phase extraction,
reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat
blood. J Pharm Biomed Anal. 1997 Mar;15(6):749-58. doi:
10.1016/s0731-7085(96)01899-7. PMID: 9172100.
3: Kashiwagi A. Rationale and hurdles of inhibitors of hepatic gluconeogenesis
in treatment of diabetes mellitus. Diabetes Res Clin Pract. 1995 Aug;28
Suppl:S195-200. doi: 10.1016/0168-8227(95)01079-s. PMID: 8529514.
4: Belardinelli L, Lu J, Dennis D, Martens J, Shryock JC. The cardiac effects of
a novel A1-adenosine receptor agonist in guinea pig isolated heart. J Pharmacol
Exp Ther. 1994 Dec;271(3):1371-82. PMID: 7996449.
5: Bertolet BD, Anand IS, Bryg RJ, Mohanty PK, Chatterjee K, Cohn JN, Khurmi NS,
Pepine CJ. Effects of A1 adenosine receptor agonism using
N6-cyclohexyl-2'-O-methyladenosine in patients with left ventricular
dysfunction. Circulation. 1996 Sep 15;94(6):1212-5. doi:
10.1161/01.cir.94.6.1212. PMID: 8822971.
6: Ishikawa J, Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S. Hypoglycemic
and hypotensive effects of 6-cyclohexyl-2'-O-methyl-adenosine, an adenosine A1
receptor agonist, in spontaneously hypertensive rat complicated with
hyperglycemia. Diabetes Res Clin Pract. 1998 Jan;39(1):3-9. doi:
10.1016/s0168-8227(97)00116-2. PMID: 9597368.
7: Librán-Pérez M, Velasco C, Otero-Rodiño C, López-Patiño MA, Míguez JM,
Soengas JL. Metabolic response in liver and Brockmann bodies of rainbow trout to
inhibition of lipolysis; possible involvement of the hypothalamus-pituitary-
interrenal (HPI) axis. J Comp Physiol B. 2015 May;185(4):413-23. doi:
10.1007/s00360-015-0894-8. Epub 2015 Feb 10. PMID: 25666862.
